Amgen Tops Fourth-Quarter Profit Estimates, Raises Guidance

  • Adjusted EPS totals $2.61, beating predictions for $2.29
  • Biotech giant maintains growth with six new drugs in 2015

Amgen Inc. posted fourth-quarter profit that easily topped analysts’ estimates as its operating margin widened. The biotechnology giant also raised its guidance for 2016 earnings.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.